Global Meloxicam Market Size By Type (Combination Drugs, Prescribed Drugs), By Application (Rheumatoid Arthritis, Osteoarthritis), By Region, And Segment Forecasts, 2023 to 2032

The Global Meloxicam Market was valued at USD 1.8 billion in 2023 and is projected to surpass USD 2.9 billion by 2031, growing at a CAGR of 6.2% during the forecast period from 2023 to 2031. The market is driven by the increasing prevalence of osteoarthritis, rheumatoid arthritis, and other inflammatory conditions, along with the growing aging population and rising awareness regarding nonsteroidal anti-inflammatory drugs (NSAIDs). Meloxicam, a commonly prescribed NSAID, has gained widespread acceptance due to its long duration of action, selective COX-2 inhibition, and lower gastrointestinal side effects compared to traditional NSAIDs.

Drivers:

1. Rising Prevalence of Arthritis and Musculoskeletal Disorders:

The increasing global burden of arthritis and chronic musculoskeletal pain has significantly contributed to the demand for effective and long-lasting pain relief options. Meloxicam is a preferred choice among healthcare providers due to its efficacy and tolerability profile.

2. Growing Geriatric Population:

As the global population ages, age-related conditions like osteoarthritis become more common. Older adults often require long-term management of inflammation and pain, making meloxicam a critical therapeutic agent in geriatrics.

3. Increasing Demand for Generic NSAIDs:

The growing cost pressures in healthcare systems and the increasing availability of generic versions of meloxicam are driving market accessibility and penetration, especially in price-sensitive regions.

Restraints:

1. Risk of Side Effects and Safety Concerns:

Despite its benefits, meloxicam carries potential risks including cardiovascular events and renal complications, particularly with long-term use. These safety concerns may limit its usage in certain populations.

2. Regulatory and Compliance Challenges:

Stringent regulations around NSAIDs, including labeling requirements and adverse event monitoring, can pose challenges for manufacturers and restrict market growth in certain regions.

Opportunity:

1. Expansion in Emerging Markets:

Emerging economies in Asia-Pacific, Latin America, and Africa present lucrative growth opportunities due to rising healthcare spending, improving access to medications, and increasing diagnosis of inflammatory diseases.

2. Development of Novel Drug Delivery Systems:

Innovations such as extended-release formulations, transdermal patches, and orally disintegrating tablets could enhance patient compliance and broaden market appeal.

Market by System Type Insights:

Based on system type, the oral tablets segment held the largest share of the meloxicam market in 2023. The popularity of tablets is attributed to their convenience, consistent dosing, and wide availability. However, the injectable formulation is anticipated to witness notable growth due to its application in acute care settings and for patients with severe pain episodes who require rapid relief.

Market by End-use Insights:

In terms of end-use, the hospital pharmacies segment accounted for the largest revenue share in 2023. Hospitals represent a primary point of care for severe pain and inflammation management, where meloxicam is administered for both inpatients and surgical recovery cases. The retail pharmacies segment is also expected to grow, driven by increasing prescriptions in outpatient settings.

Market by Regional Insights:

Regionally, North America dominated the global meloxicam market in 2023, driven by high awareness, established healthcare infrastructure, and significant R&D activities. Asia-Pacific is forecasted to be the fastest-growing region during the forecast period due to increasing healthcare access, population growth, and rising incidence of arthritis and chronic pain disorders.

Competitive Scenario:

Prominent players in the global meloxicam market include Boehringer Ingelheim, Teva Pharmaceuticals, Mylan N.V. (a Viatris company), Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals, and Amneal Pharmaceuticals. These companies are focusing on portfolio expansion, regulatory approvals, and competitive pricing strategies.

Key Developments:

In 2023, Teva Pharmaceuticals launched an extended-release version of meloxicam in the U.S. market to enhance patient adherence.

In 2022, Lupin received FDA approval for a generic meloxicam injection, expanding its hospital-focused portfolio.

In 2024, Sun Pharma announced the development of a meloxicam oral disintegrating tablet aimed at elderly patients with dysphagia.

Scope of Work – Global Meloxicam Market

Report Metric Details

Market Size (2023) USD 1.8 billion

Projected Market Size (2031) USD 2.9 billion

CAGR (2023–2031) 6.2%

Market Segments System Type (Oral Tablets, Injectables), End-Use (Hosp